CN113288951A - 一种升血中药组合物及其制备方法 - Google Patents
一种升血中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113288951A CN113288951A CN202110723262.0A CN202110723262A CN113288951A CN 113288951 A CN113288951 A CN 113288951A CN 202110723262 A CN202110723262 A CN 202110723262A CN 113288951 A CN113288951 A CN 113288951A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood
- traditional chinese
- deficiency
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 146
- 239000008280 blood Substances 0.000 claims abstract description 146
- 230000007812 deficiency Effects 0.000 claims abstract description 97
- 210000000952 spleen Anatomy 0.000 claims abstract description 67
- 210000003734 kidney Anatomy 0.000 claims abstract description 62
- 239000003292 glue Substances 0.000 claims abstract description 26
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 20
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 20
- 241000132012 Atractylodes Species 0.000 claims abstract description 19
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 19
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 19
- 235000011477 liquorice Nutrition 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 235000017060 Arachis glabrata Nutrition 0.000 claims abstract description 17
- 244000105624 Arachis hypogaea Species 0.000 claims abstract description 17
- 235000010777 Arachis hypogaea Nutrition 0.000 claims abstract description 17
- 235000018262 Arachis monticola Nutrition 0.000 claims abstract description 17
- 235000020232 peanut Nutrition 0.000 claims abstract description 17
- 201000002364 leukopenia Diseases 0.000 claims abstract description 15
- 231100001022 leukopenia Toxicity 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 8
- 208000032467 Aplastic anaemia Diseases 0.000 claims abstract description 7
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims abstract description 6
- 238000002512 chemotherapy Methods 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 22
- 241000405414 Rehmannia Species 0.000 claims description 14
- 210000003056 antler Anatomy 0.000 claims description 14
- 241001061264 Astragalus Species 0.000 claims description 13
- 210000004233 talus Anatomy 0.000 claims description 13
- 208000014951 hematologic disease Diseases 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 206010065553 Bone marrow failure Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 206010033661 Pancytopenia Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000024389 cytopenia Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000016993 Agrimonia Nutrition 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 44
- 201000010099 disease Diseases 0.000 description 43
- 210000000265 leukocyte Anatomy 0.000 description 39
- 208000024891 symptom Diseases 0.000 description 28
- 208000011580 syndromic disease Diseases 0.000 description 26
- 230000004069 differentiation Effects 0.000 description 23
- 206010016256 fatigue Diseases 0.000 description 23
- 206010012735 Diarrhoea Diseases 0.000 description 22
- 230000017423 tissue regeneration Effects 0.000 description 22
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 21
- 206010022437 insomnia Diseases 0.000 description 21
- 206010029446 nocturia Diseases 0.000 description 21
- 230000003203 everyday effect Effects 0.000 description 20
- 230000036528 appetite Effects 0.000 description 18
- 235000019789 appetite Nutrition 0.000 description 18
- 210000001185 bone marrow Anatomy 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 210000001772 blood platelet Anatomy 0.000 description 14
- 208000000059 Dyspnea Diseases 0.000 description 13
- 206010013975 Dyspnoeas Diseases 0.000 description 13
- 208000006083 Hypokinesia Diseases 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 210000003414 extremity Anatomy 0.000 description 12
- 230000002269 spontaneous effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 208000008035 Back Pain Diseases 0.000 description 9
- 238000009534 blood test Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 206010003549 asthenia Diseases 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 210000003127 knee Anatomy 0.000 description 7
- 241001550206 Colla Species 0.000 description 6
- 241000209020 Cornus Species 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 4
- 208000019914 Mental Fatigue Diseases 0.000 description 4
- 208000019804 backache Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000002313 intestinal cancer Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 241000431987 Neocheiropteris fortunei Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010018276 Gingival bleeding Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000017243 gastric diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 208000027905 limb weakness Diseases 0.000 description 2
- 231100000861 limb weakness Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种中药组合物,由以下重量份的中药材制备而成:黄芪30‑60份、党参30‑60份、白术10‑20份、茯苓10‑20份、当归10‑20份、骨碎补10‑20份、鹿角胶(烊化)6‑9份、熟地10‑20份、陈皮10‑20份、仙鹤草20‑30份、鸡血藤20‑30份、花生衣3‑6份和甘草4‑6份。该组合物适用于脾肾两虚、气血亏虚和/或气虚血瘀患者,改善因血液病导致三系减少、再生障碍性贫血、血小板减少症、白细胞减少症。
Description
技术领域
本发明属于中药领域,具体涉及一种升血中药组合物及其制备方法。
背景技术
目前,化疗仍是恶性肿瘤治疗的重要方法之一,化疗药物在杀灭肿瘤细胞的同时也损伤正常细胞,对于增殖较快的骨髓造血干细胞的损伤最为显著。导致患者出现骨髓抑制,表现为白细胞减少、贫血、血小板减少。血液系统疾病,因其本身发病机制,临床也可表现为全血减少等。严重的白细胞减少可导致患者合并感染,而血小板低下导致患者出现自发出血,重度贫血可危及患者生命。同时严重的骨髓抑制可能导致患者推迟化疗周期,减少化疗药物剂量,影响最终治疗效果,因此有效防治化疗后骨髓抑制以及改善血液系统疾病三系减少的手段非常重要。
西医运用于改善三系减少的手段主要为使用造血细胞集落刺激因子、对症输血及激素治疗等。粒细胞刺激因子、促血小板生成素、重组人白介素-11等药物在临床的广泛使用,在一定程度上改善了患者的临床症状,但此类药物容易加速耗竭造血干细胞,大量长期使用有导致真性红细胞增多和慢性粒细胞白血病等发病风险。输血治疗可迅速起到治疗作用,但成分输血对指标要求多,且可能出现输血反应,甚至出现血源性感染等。小剂量激素治疗,如使用地塞米松等,疗效不明显,副反应较大。因此西医治疗远期疗效不稳定,毒副反应明显,价格昂贵等缺点突出。大量的文献显示,中医药治疗恶性肿瘤化疗后导致患者出现骨髓抑制,以及血液系统疾病三系减少有其独特的优势及较好的疗效。
血液系统疾病及化疗后骨髓抑制归属于中医学“虚劳”、“血劳”、“血证”等范畴。主要是由于先天禀赋正气不足,加之后天受化疗药物药毒内侵,化疗药是有毒之品,其性峻力猛,在攻伐机体癌毒的同时,也加重了气血脏腑的损伤,尤其是脾肾两脏,导致正气耗伤,脾失健运、肾失气化,气血生化无源,最终导致气血亏虚之证候。邪毒直中骨髓,导致髓亏肾虚精耗,先天之本枯竭;邪毒损及中焦脾胃,脾胃功能受损,脾失健运,胃失和降,致使后天之本已衰,气血生化无源,致气血亏虚;血液系统疾病及恶性肿瘤多疗程化疗后,病程长,病情重,以虚证为多见,我们观察到以脾肾两虚、气血亏虚为主。“虚久必瘀,瘀久必虚,两者互为因果,形成病理上的恶性循环,表现为虚实夹杂的服装病理过程。
因此我们认为血液系统疾病及恶性肿瘤多疗程化疗后的贫血多以脾肾亏虚为主,主要部位在骨髓,在脏为髓,在象为血,以脾肾虚损为主,气血亏虚为外候,治疗多以健脾补肾为主,虚久必瘀,气虚血瘀,因此临床提出了健脾补肾,益气补血,祛瘀生新的治疗方法。
发明内容
本发明的目的在于提供一种升血中药组合物及其制备方法。
为实现本发明的目的,提供如下实施方案。
本发明的一种中药组合物,由以下重量份的中药材制备而成:黄芪30-60份、党参30-60份、白术10-20份、茯苓10-20份、当归 10-20份、骨碎补10-20份、鹿角胶(烊化)6-9份、熟地10-20份、陈皮10-20份、仙鹤草20-30份、鸡血藤20-30份、花生衣3-6份和甘草4-6份。
上述本发明的中药组合物,优选的,主要由以下重量份的中药材制备而成:黄芪30份、党参30份、白术15份、茯苓15份、当归 10份、骨碎补15份、鹿角胶6份(烊化)、熟地15份、陈皮15份、仙鹤草30份、鸡血藤30份、花生衣5份,和甘草6份。
在一具体实施方案中,本发明的中药组合物,主要由以下重量份的中药材制备而成,黄芪30g、党参30g、白术15g、茯苓15g、当归 10g、骨碎补15g、鹿角胶6g(烊化)、熟地15g、陈皮15g、仙鹤草 30g、鸡血藤30g、花生衣5g和甘草6g。
上述本发明的中药组合物,可制成的口服制剂形式包括汤剂、胶囊、片剂、丸剂或颗粒剂。
所述制剂按常规制剂技术制造,根据实际需要,可加入相应适量的药用辅料,如填充剂、崩解剂、粘合剂、润滑剂等,辅料种类都是本领域常用辅料如淀粉、糊精等。
另一方面,本发明的目的还提供了一种制备本发明的中药组合物的方法,包括以下步骤:
⑴称取处方量的鹿角胶,冷冻粉碎,过筛,得鹿角胶粉;
⑵称取处方的黄芪、党参、白术、茯苓、当归、骨碎朴、熟地黄、陈皮、甘草、仙鹤草、鸡血藤,洗净,灭菌,放入适当容器内,加水 5~10倍,用文火煎煮20-24小时,滤去渣,再将滤液用文火煎熬,不断搅拌,浓缩成浸膏;
⑶将步骤⑵制得的浸膏继续浓缩至40℃的相对密度为1.15~ 1.30g/cm3,加入鹿角胶粉,以及糊精适量,混匀,减压干燥(60℃,-0.1Mpa),粉碎,得细粉;
⑷将步骤⑶制得的细粉制成口服制剂。
上述本发明的方法,步骤(3)中所述减压干燥,温度为60℃,压力为-0.1Mpa。
本发明的中药组合物在制造治疗血液疾病药物中的用途。所述血液疾病包括因血液病导致三系减少,再生障碍性贫血、血小板减少症、白细胞减少症、骨髓增生异常综合症及放、化疗引起的骨髓抑制后血细胞减少,属脾肾两虚,气血亏虚,气虚血瘀患者。
本发明的中药组合物用于再生障碍性贫血、血小板减少症、白细胞减少症、骨髓增生异常综合症及放、化疗引起的骨髓抑制后血细胞减少,属脾肾两虚,气血亏虚,气虚血瘀患者。提升患者的血小板、白细胞量。
本发明的升血中药组合物方解
处方:黄芪30g、党参30g、白术15g、茯苓15g、当归10g、骨碎补15g、鹿角胶6g(烊化)、熟地15g、陈皮15g、仙鹤草30g、鸡血藤30g、花生衣5g,甘草6g。
方中当归补血汤补气生血,故为君药,黄芪补中益气,健脾升阳,当归,专门补血养血,是补血之圣药。
方中四君子汤与骨碎补、鹿角胶、熟地和陈皮共为臣药,“脾胃后天之本,气血生化之源”,方中四君子汤,出自《太平惠民和剂局方》,有益气健脾之功,党参补气健脾、养血生精,白术、茯苓健脾和胃,养血安神,助力黄芪补气健脾养血之用。
“肾主骨生髓”,“精血同源”,骨碎补补肾壮骨,熟地具有滋阴补肾,补气养血的功效,鹿角胶有补益肝肾、填精生髓的作用。
陈皮理气健脾,以防止补肾养血之品过于滋腻。
仙鹤草、鸡血藤与花生衣共为佐药,血液疾病病程长,“久病必瘀”,“虚久必瘀”“瘀血不去,新血不生”,故多有瘀血的征象,故鸡血藤有补血,活血,通络的作用,仙鹤草收敛止血,补虚强壮,“脾主统血”,脾气虚的人就容易出血,花生衣为花生的红色外皮,具有止血、散瘀、养血的作用,治疗各种出血的病症。
甘草为使药,调和诸药。全方共达益气健脾,补肾填精,滋养精血之功。
本发明的升血中药组合物,适用于脾肾两虚,气血亏虚,气虚血瘀患者和血液疾病患者。给血液疾病患者,特别是血液三系减少患者服用每日一剂,每日分1-3次口服,连服1周到一月。显示出良好的效果。三系减少指的是红系,粒系以及巨核系,相对应的血常规的表现为红细胞,白细胞以及血小板,也就指的是外周血全血细胞减少。
具体实施方式
以下实施例仅是代表性的,用于进一步说明和理解本发的精神实质,但不以此限制本发明的范围。
实施例1汤剂
升血中药组合物处方(1剂方子的处方量)
黄芪30g、党参30g、白术15g、茯苓15g、当归10g、骨碎补15g、鹿角胶6g(烊化)、熟地15g、陈皮15g、仙鹤草30g、鸡血藤30g、花生衣5g,甘草6g。
将上方子中除鹿角胶外的药材用水按常规熬药方法熬水,1剂熬 3次,3次药液混合,称取鹿角胶烊化,冷冻粉碎,过筛,得鹿角胶粉,加入药液中制得汤剂,日分3次早中晚服用。
实施例2胶囊剂
组合物配方:
黄芪30-60份、党参30-60份、白术10-20份、茯苓10-20份、当归10-20份、骨碎补10-20份、鹿角胶(烊化)6-9份、熟地10-20 份、陈皮10-20份、仙鹤草20-30份、鸡血藤20-30份、花生衣3-6 份和甘草4-6份。
胶囊剂制备方法:
微粉硅胶适量
制法:
(1)配比称取鹿角胶,冷冻粉碎,过筛,得鹿角胶粉;
⑵按配比称取黄芪、党参、白术、茯苓、当归、骨碎朴、熟地黄、陈皮、甘草、仙鹤草、鸡血藤,洗净,灭菌,放入适当容器内,加 10倍量水,用文火煎煮24小时,滤去渣,再将滤液用文火煎熬,不断搅拌,浓缩成浸膏;
⑶将步骤⑵制得的浸膏继续浓缩至相对密度为1.15~ 1.30g/cm3(40℃),加入鹿角胶粉,以及糊精适量,混匀,减压干燥 (60℃,-0.1Mpa),粉碎,得细粉;
⑷将步骤⑶制得的细粉加入微粉硅胶,混匀,装胶囊。
实施例3颗粒剂
中药配方(1剂单位处方以g计):
黄芪30份、党参30份、白术15份、茯苓15份、当归10份、骨碎补15份、鹿角胶6份(烊化)、熟地15份、陈皮15份、仙鹤草30 份、鸡血藤30份、花生衣5份,和甘草6份
制备方法:
糊精适量
制法:
⑴按配比称取鹿角胶,冷冻粉碎,过筛,得鹿角胶粉;
⑵按配比称取黄芪、党参、白术、茯苓、当归、骨碎朴、熟地黄、陈皮、甘草、仙鹤草、鸡血藤,洗净,灭菌,放入适当容器内,加 10倍量水,用文火煎煮24小时,滤去渣,再将滤液用文火煎熬,不断搅拌,浓缩成浸膏;
⑶将步骤⑵制得的浸膏继续浓缩至相对密度为1.15~ 1.30g/cm3(40℃),加入鹿角胶粉,以及糊精适量,混匀,减压干燥 (60℃,-0.1Mpa),粉碎,得细粉;
⑷将步骤⑶制得的细粉制粒,装袋。
日服相当于1剂方子的颗粒的量,分3次早中晚服用。
实施例3片剂
配方:黄芪40份、党参40份、白术10份、茯苓10份、当归 20份、骨碎补10份、鹿角胶(烊化)7份、熟地10份、陈皮10份、仙鹤草20份、鸡血藤20份、花生衣6份和甘草5份。
或者
黄芪60份、党参60份、白术20份、茯苓20份、当归15份、骨碎补20份、鹿角胶(烊化)9份、熟地20份、陈皮20份、仙鹤草 25份、鸡血藤25份、花生衣3份和甘草4份
制备方法:
⑴按配比称取鹿角胶,冷冻粉碎,过筛,得鹿角胶粉;
⑵按配比称取黄芪、党参、白术、茯苓、当归、骨碎朴、熟地黄、陈皮、甘草、仙鹤草、鸡血藤,洗净,灭菌,放入适当容器内,加 10倍量水,用文火煎煮24小时,滤去渣,再将滤液用文火煎熬,不断搅拌,浓缩成浸膏;
⑶将步骤⑵制得的浸膏继续浓缩至相对密度为1.15~ 1.30g/cm3(40℃),加入鹿角胶粉,以及糊精适量,混匀,减压干燥 (60℃,-0.1Mpa),粉碎,得细粉;
⑷将步骤⑶制得的细粉加入淀粉适量制粒压片。
试验例1用于血液疾病治疗
给以下患者服用实施例1的汤剂(称升血汤),日服1剂,分3 次早、中、晚服用,试验例中的三系降低是指红细胞,白细胞以及血小板明显低于正常范围值。
1、彭女士,67岁,因反复心慌乏力5+年,加重1+月就诊,近5 年来三系降低,常予以输血、血小板,升白细胞治疗,表现为望之少神,面色苍白,肢软乏力,语声低微,全身皮肤可见多处瘀斑,纳差,夜寐不安,夜尿3次,腰膝酸软,大便稀溏,3次/天,双下肢水肿。舌淡红,苔薄白,脉细弱。西医诊断:重型再生障碍性贫血,中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年8月治疗输血小板,同时口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定,未再住院输血。
2、陈先生,80岁,因反复皮肤瘀斑、牙龈出血7年,加重半年就诊。近半年来三系降低,常予以输血、血小板,升白细胞治疗,临床表现;神倦乏力,语声低微,全身皮肤可见多处瘀斑,牙龈出血,动则喘累,呼吸困难,端坐位呼吸,纳差,夜寐不安,夜尿頻数,腰膝酸软,大便稀溏,1次/天,双下肢水肿。舌淡紫,苔薄白,脉细弱。西医诊断:原发免疫性血小板减少症骨髓增生异常综合征?,中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2021年1月治疗输血小板,同时口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定。
3、刘女士,73岁,因头昏20+年,乏力1+年就诊。加重半月就诊。临床表现;神倦乏力,头昏,语声低微,面色苍白,动则喘累,纳差不是饮食,失眠多梦,夜尿每晚3次,腰膝酸软,大便稀溏,2 次/天,舌淡紫,苔薄白,脉细弱。西医诊断:大颗粒淋巴细胞性白血病T细胞型,中医诊断:虚劳,中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年12月治疗输血细胞悬液,同时口服升血汤,每日1剂,连服一月,症状好转,1年来病情稳定。
4、李先生,51岁,因反复乏力2年,加重3天就诊。近2年来三系降低,常予以输血、血小板,升白细胞治疗,临床表现;神倦乏力,面色苍白,语声低微,动则喘累,纳差食少,失眠多梦,夜尿每晚3次,腰膝酸软,大便稀溏,3次/天,舌淡紫,苔薄白,脉细弱。西医诊断:再生障碍性贫血(重型),中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2021年3月输红细胞悬液及血小板,同时口服升血汤,每日1 剂,连服一月,症状好转,半年来病情稳定。
5、张女士,70岁,因反复乏力10余年,加重伴心累3天就诊。近10年来三系降低,常予以输血、血小板,升白细胞治疗,临床表现:精神萎靡,肢软乏力,语声低微,心慌心累,动则加重,不思饮食,夜寐不安,夜尿2次,腰膝酸软,大便稀溏,3次/天,双下肢水肿。舌淡紫,苔薄白,脉细弱。西医诊断:再生障碍性贫血,中医诊断:虚劳,中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗:输红细胞悬液,2021年3月口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定。
6、张女士,46岁,因急性淋巴细胞白血病9+月,末次化疗后1 月就诊。临床表现:精神较差,肢软乏力,语声低微,面色苍白,动则心累,纳差食少,夜寐不安,夜尿2次,腰膝酸软,大便稀溏,2 次/天,双下肢水肿。舌淡紫,苔薄白,脉细弱。西医诊断:急性B 淋巴细胞性白血病,中医诊断:虚劳,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年10 月口服升血汤,每日1剂,连服一月,症状好转,1年来病情稳定。
7、杨女士,79岁,因多发性骨髓瘤5+年,食欲下降1月就诊。临床表现:神倦乏力,语声低微,面色苍白,心累胸闷,食欲下降,夜寐不安,夜尿2次,动则汗出,腰膝酸软,大便稀溏,2次/天,双下肢水肿。舌淡紫,苔薄白,脉细弱。西医诊断:多发性骨髓瘤Kappa 型IIIa型,中医诊断:骨痹,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗:输红细胞悬液,2020年5月口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定。
8、魏女士,67岁,因乏力,腰痛1+年,手指麻木半月就诊。临床表现:神倦乏力,语声低微,面色苍白,手指麻木,纳差食少,失眠多梦,夜尿3次,腰痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。西医诊断:多发性骨髓瘤,中医诊断:骨痹,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年7月口服升血汤,每日1剂,连服一月而治愈,症状好转,1年来病情稳定。
9、彭先生,82岁,因确诊多发性骨髓瘤2+年,乏力、纳差2天就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,纳差食少,失眠不易入睡,多梦,夜尿4次,腰酸背痛,大便稀溏,3次 /天,舌淡紫,苔薄白,舌下络脉瘀曲,脉细弱。西医诊断:多发性骨髓瘤,中医诊断:骨痹,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年5月口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定。
10、钱女士,65岁,因反复腰痛4+年,末次化疗后1月就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗明显,夜尿3次,腰酸背痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。西医诊断:多发性骨髓瘤,中医诊断:骨瘤,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年11月口服升血汤,每日1剂,连服一月,症状好转,半年来病情稳定。
11、周女士,65岁,因反复乏力、自汗6月余,加重1月就诊。临床表现:精神欠佳,肢软乏力,面色苍白,动则汗出,偶有耳鸣,纳食欠佳,失眠多梦,大便稀溏,日3—4次,夜尿頻数,每晚3—4 次。舌淡红,苔白微腻,舌下络脉瘀曲,脉细弱。西医诊断:急性髓系白血病(M4),中医诊断:虚劳,中医辨证:脾肾两虚,气血不足,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年12月口服升血汤,每日1剂,连服一月,复查白细胞恢复正常,症状好转,病情稳定。
12、李女士,63岁,因确诊免疫性血小板减少1+月就诊。临床表现:患者精神欠佳,胸闷、乏力,纳差,失眠,大小便正常。舌淡紫,苔白腻,脉细弱。西医诊断:免疫性血小板减少,中医诊断:虚劳,中医辨证:脾肾两虚,气血不足,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。2020年12月口服升血汤,每日1剂,连服一月,复查血小板恢复正常,症状好转,病情稳定。
13、王先生,66岁,因确诊骨髓增生异常综合征伴全身乏力3 年余,加重1周就诊。近三年来三系降低,常予以输血、血小板,升白细胞治疗,临床表现:精神状态差,面色苍白,体重下降,全身皮肤可见多处瘀点,饮食不佳,夜寐不安,动则气喘汗出,双下肢水肿,大便稀溏,日2—3次,小便清长,舌淡紫红,苔薄白,脉细弱。西医诊断:骨髓增生异常综合征(REAB-1I高危组),中医诊断:虚劳,中医辨证:脾肾两虚,气血不足,法则:健脾补肾,益气养血。治疗予支持对症治疗,输红细胞悬液及血小板,同时口服升血汤,每日1剂,连服3月,复查血常规均恢复正常,症状好转,半年来病情稳定。
试验例2其他肿瘤化疗后骨髓抑制(采用实施全1的汤剂,日服1 剂,分3次早、中、晚服用)
1、李女士,68岁,因左侧副乳癌术后15+年,复发2年,化疗后1周,于2020年4月就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,自汗,纳差食少,失眠多梦,夜尿4次,颈腰背疼痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:2.64*109/L,Hb:109g/L,PLT:178*109/L。西医诊断:左副乳癌术后化疗后伴全身多处骨转移,化疗后骨髓抑制,中医诊断:乳癌中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服1 月,症状好转,白细胞恢复正常,WBC:4.27*109/L,Hb:110g/L, PLT:198*109/L,病情稳定。
2、蒋先生,67岁,因结肠癌术后1+年,末次化疗后1月,于 2021年2月就诊。临床表现:神倦乏力,面色苍白,纳差食少,失眠多梦,夜尿3次,腰酸背痛,大便稀溏,4次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:3.42*109/L,Hb:132g/L, PLT:142*109/L。西医诊断:直乙状结肠交界处腺癌术后复发化疗后伴肝转移,化疗后骨髓抑制,中医诊断:肠癌中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC: 6.42*109/L,Hb:136g/L,PLT:156*109/L,病情稳定。
3、江女士,53岁,因确诊左肺腺癌近2年,末次化疗后1月,于2020年1月就诊。临床表现:精神疲倦,肢软乏力,动则喘累,面色苍白,纳食减少,夜寐不安,失眠多梦,夜尿2次,腰背疼痛,大便稀溏,1次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:2.93*109/L,Hb:106g/L,PLT:125*109/L。西医诊断:右肺鳞癌伴多处转移化疗后化疗后骨髓抑制,中医诊断:肺癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:7.29*109/L,Hb:107g/L,PLT:127*109/L,病情稳定。
4、邹先生,63岁,因有肺癌术后1年余,末次化疗后1月,于 2021年2月就诊。临床表现:肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗,夜尿3次,腰酸背痛,大便稀溏,3次/ 天,舌淡紫,苔白,脉细弱。查血常规白细胞减少,WBC:2.38*109/L, Hb:93g/L,PLT:200*109/L。西医诊断:左肺腺癌IV期骨转移,化疗后骨髓抑制,中医诊断:肺癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:6.87*109/L, Hb:115g/L,PLT:184*109/L,病情稳定。
5、余女士,57岁,因确诊右肺癌3年,末次化疗后1+月,于 2020年2月就诊。临床表现:精神较差,肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗,夜尿3次,腰酸背痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC: 2.45*109/L,Hb:105g/L,PLT:105*109/L。西医诊断:右肺腺癌伴全身广泛转移,中医诊断:肺癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:6.41*109/L, Hb:109g/L,PLT:170*109/L,病情稳定。
6、夏女士,83岁,因确诊结肠癌2年,末次化疗后40+天,于 2020年8月就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗明显,夜尿3次,腰酸背痛,大便稀溏,夹不消化物,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:2.88*109/L,Hb:125g/L,PLT:115*109/L。西医诊断:乙状结肠腺癌化疗后,化疗后骨髓抑制,中医诊断:肠癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:4.08*109/L,Hb:132g/L,PLT:139*109/L。病情稳定。
7、罗女士,77岁,因确诊结肠癌9+月,末次化疗后1周,于 2020年10月就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗明显,夜尿3次,腰酸背痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少, WBC:2.64*109/L,Hb:96g/L,PLT:185*109/L。西医诊断:乙状结肠腺癌,化疗后骨髓抑制,中医诊断:肠癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC: 4.64*109/L,Hb:105g/L,PLT:171*109/L,病情稳定。
8、陈先生,55岁,因确诊胃弥漫大B细胞淋巴瘤7月余,末次化疗后伴全身乏力半月,于2021年1月就诊。临床表现:精神倦怠,肢软乏力,面色苍白,纳食减少,夜寐不安,自汗,夜尿2次,腰酸痛,大便稀溏,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:2.71*109/L,Hb:108g/L,PLT:172*109/L。西医诊断:胃弥漫大B细胞淋巴瘤,化疗后骨髓抑制,中医诊断:胃淋巴瘤,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:4.62*109/L,Hb:100g/L,PLT:136*109/L,病情稳定。
9、曾女士,53岁,因直肠癌术后3年余,末次化疗后20余天,于2021年2月就诊。临床表现:精神较差,肢软乏力,动则自汗,面色苍白,纳差食少,失眠多梦,夜尿3次,腰酸背痛,大便稀溏,夹不消化物,2次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞、血小板减少,WBC:2.20*109/L,Hb:107g/L,PLT:86*109/L。西医诊断:直肠腺癌术后化疗后复发伴双肺转移,化疗后骨髓抑制,中医诊断:肠癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日1剂,连服半月,症状好转,白细胞恢复正常,WBC:4.88*109/L,Hb:131g/L, PLT:97*109/L。病情稳定。
10、葛女士,50岁,因右乳腺癌术后3年余,颅内转移2年,伽玛刀放疗后1周,于2020年9月就诊。临床表现:精神倦怠,肢软乏力,动则喘累,面色苍白,纳差食少,失眠多梦,自汗,言语欠清,夜尿3次,腰背酸痛,大便稀溏,3次/天,舌淡紫,苔薄白,脉细弱。查血常规白细胞减少,WBC:2.02*109/L,Hb:125g/L,PLT: 135*109/L。西医诊断:左乳浸润性癌伴颅内转移化疗后,化疗后骨髓抑制,中医诊断:乳癌,中医辨证:脾肾两虚,气血亏虚,气虚血瘀,法则:健脾补肾,益气养血,祛瘀生新。治疗口服升血汤,每日一剂,连服半月,症状好转,白细胞恢复正常,WBC:8.69*109/L, Hb:133g/L,PLT:137*109/L,病情稳定。
Claims (9)
1.一种中药组合物,主要由以下重量份的中药材制备而成:黄芪30-60份、党参30-60份、白术10-20份、茯苓10-20份、当归10-20份、骨碎补10-20份、鹿角胶(烊化)6-9份、熟地10-20份、陈皮10-20份、仙鹤草20-30份、鸡血藤20-30份、花生衣3-6份和甘草4-6份。
2.如权利要求1的中药组合物,主要由以下重量份的中药材制备而成:黄芪30份、党参30份、白术15份、茯苓15份、当归10份、骨碎补15份、鹿角胶6份(烊化)、熟地15份、陈皮15份、仙鹤草30份、鸡血藤30份、花生衣5份,和甘草6份。
3.如权利要求1的中药组合物,主要由以下重量份的中药材制备而成,黄芪30g、党参30g、白术15g、茯苓15g、当归10g、骨碎补15g、鹿角胶6g(烊化)、熟地15g、陈皮15g、仙鹤草30g、鸡血藤30g、花生衣5g和甘草6g。
4.如权利要求1-3任一所述的中药组合物,可制成的口服制剂形式包括胶囊、片剂、丸剂或颗粒剂。
5.一种制备权利要求3的中药组合物的方法,包括以下步骤:
⑴称取处方量的鹿角胶,冷冻粉碎,过筛,得鹿角胶粉;
⑵称取处方的黄芪、党参、白术、茯苓、当归、骨碎朴、熟地黄、陈皮、甘草、仙鹤草、鸡血藤,洗净,灭菌,放入适当容器内,加水5~10倍,用文火煎煮20-24小时,滤去渣,再将滤液用文火煎熬,不断搅拌,浓缩成浸膏;
⑶将步骤⑵制得的浸膏继续浓缩至40℃的相对密度为1.15~1.30g/cm3,加入鹿角胶粉,以及糊精适量,混匀,减压干燥(60℃,-0.1Mpa),粉碎,得细粉;
⑷将步骤⑶制得的细粉制成口服制剂。
6.如权利要求5所述的方法,步骤(3)中所述减压干燥,温度为60℃,压力为-0.1Mpa。
7.权利要求1-3任一所述的中药组合物在制造治疗血液疾病的药物中的用途。
8.如权利要求7所述的用途,所述血液疾病包括因血液病导致三系减少、再生障碍性贫血、血小板减少症、白细胞减少症、骨髓增生异常综合症及放、化疗引起的骨髓抑制后血细胞减少。
9.如权利要求7或8所述的用途,所述血液疾病属于脾肾两虚、气血亏虚和/或气虚血瘀患者。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110723262.0A CN113288951A (zh) | 2021-06-28 | 2021-06-28 | 一种升血中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110723262.0A CN113288951A (zh) | 2021-06-28 | 2021-06-28 | 一种升血中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113288951A true CN113288951A (zh) | 2021-08-24 |
Family
ID=77329881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110723262.0A Pending CN113288951A (zh) | 2021-06-28 | 2021-06-28 | 一种升血中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113288951A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840006A (zh) * | 2006-01-26 | 2006-10-04 | 周伟 | 治疗再生障碍性贫血的药物 |
CN104127550A (zh) * | 2014-08-18 | 2014-11-05 | 青岛市市立医院 | 一种治疗放化疗所致血小板减少的药物及其制备方法 |
CN111773286A (zh) * | 2020-07-30 | 2020-10-16 | 济宁食行天下食品有限公司 | 一种治疗贫血的中药制剂及其制作方法 |
-
2021
- 2021-06-28 CN CN202110723262.0A patent/CN113288951A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840006A (zh) * | 2006-01-26 | 2006-10-04 | 周伟 | 治疗再生障碍性贫血的药物 |
CN104127550A (zh) * | 2014-08-18 | 2014-11-05 | 青岛市市立医院 | 一种治疗放化疗所致血小板减少的药物及其制备方法 |
CN111773286A (zh) * | 2020-07-30 | 2020-10-16 | 济宁食行天下食品有限公司 | 一种治疗贫血的中药制剂及其制作方法 |
Non-Patent Citations (1)
Title |
---|
陈声池: "益气补血升板方治疗化疗后血小板减少症 28 例", 《福建中医学院学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
CN102755600B (zh) | 一种抗乳腺癌转移复发中药复方及其制备方法和应用 | |
CN104161896A (zh) | 一种治疗贫血的药物组合物 | |
CN104173950A (zh) | 一种治疗前列腺癌的中草药组合物 | |
CN103223149B (zh) | 一种治疗肺癌的中草药组合物 | |
US11684631B2 (en) | Method of treating cancer with composition of traditional Chinese medicine and its preparation method thereof | |
CN113288951A (zh) | 一种升血中药组合物及其制备方法 | |
CN113368211A (zh) | 一种用于治疗犬猫肿瘤的中兽药组合物及其制备方法 | |
CN101642485B (zh) | 一种含黄芪的药物组合物在制备治疗白细胞减少症、过敏性紫癜症的药物中的应用 | |
CN104127550A (zh) | 一种治疗放化疗所致血小板减少的药物及其制备方法 | |
CN1973852B (zh) | 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 | |
CN112294940A (zh) | 一种用于治疗肿瘤的中药组合物及其应用 | |
CN108635498B (zh) | 一种用于治疗骨髓增生异常综合征的药物组合物及其应用 | |
CN113144019B (zh) | 一种治疗癌症化疗引起的白细胞减少症的中药组合物及其制备方法 | |
CN116531426B (zh) | 用于防治化疗所致白细胞减少的含硫普罗宁的药物组合物及其制备方法 | |
CN101953994B (zh) | 一种治疗放化疗后白细胞减少的中药 | |
CN114515310B (zh) | 一种预防和/或治疗放化疗所致骨髓抑制的药物组合物 | |
CN107213323B (zh) | 一种滋阴化痰、散结解毒的中药复方制剂及其用途 | |
CN106943506B (zh) | 一种治疗更年期综合征的药物组合物及其制备方法 | |
CN114129693A (zh) | 一种治疗癌症的组合物及其制备方法与应用 | |
CN105232659B (zh) | 一种疏肝健脾的中药组合物及其制备方法 | |
CN102293813B (zh) | 一种含黄芪的药物组合物在制备治疗过敏性紫癜症的药物中的应用 | |
CN105250412B (zh) | 一种疏肝健脾的中药组合物在制备治疗焦虑抑郁的药物中的应用 | |
CN114246906A (zh) | 一种中药组合物在防治骨髓抑制药物中的应用 | |
CN103751355A (zh) | 一种具有提升白细胞效果的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210824 |
|
RJ01 | Rejection of invention patent application after publication |